Stock Market Today, Feb: ImmunityBio Up on Anktiva EU OK
ImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Understanding when index funds are worth it depends on time horizon and fees. This quick guide outlines key scenarios and considerations.
14,052 articlesImmunityBio sails higher after the EU green lights ANKTIVA for bladder cancer, igniting waves across biotech stocks. ...
Reliance Industries sits at the center of India’s growth story. This guide breaks down reliance (rs) 2025 earnings ex...
In 2026, certain currencies remain prime targets for counterfeiters as cash circulates globally. Authorities are raci...
Hudbay's 2025 earnings outlook hinges on copper and zinc markets, mine costs, and capital decisions. This guide break...
New Mexico moves to examine decades of coerced sterilizations in Native communities, with findings due by 2027. The i...
Bitcoin’s calm price action has persisted through February 2026, but traders warn the lull may be masking fading ETF ...
AAPD’s 3.43% yield looks appealing, but the bear-on-Apple fund relies on collateral interest instead of dividends. A ...
Prediction markets have spoken: a strong probability Nvidia beats earnings. Learn what these odds mean, how reliable ...
A fresh AI marketing platform is launching via Reg A+ at 0.85 per share, aiming to deliver rapid ROI for large brands...
Gen Z is pushing a rebound in vinyl records and print media, shaping the market while stretching household budgets. T...
As earnings season arrives, investors focus on Axon’s path to durable growth. This article breaks down axon (axon) 20...
Yield-focused investors have chased AMDY's eye-catching yield this options strategy promises. Yet the income is volat...